全文获取类型
收费全文 | 441065篇 |
免费 | 32399篇 |
国内免费 | 13982篇 |
专业分类
耳鼻咽喉 | 4469篇 |
儿科学 | 12021篇 |
妇产科学 | 5913篇 |
基础医学 | 49501篇 |
口腔科学 | 8088篇 |
临床医学 | 44746篇 |
内科学 | 80568篇 |
皮肤病学 | 6431篇 |
神经病学 | 26035篇 |
特种医学 | 16961篇 |
外国民族医学 | 76篇 |
外科学 | 48735篇 |
综合类 | 53092篇 |
现状与发展 | 44篇 |
一般理论 | 8篇 |
预防医学 | 26572篇 |
眼科学 | 6925篇 |
药学 | 54032篇 |
170篇 | |
中国医学 | 15347篇 |
肿瘤学 | 27712篇 |
出版年
2023年 | 5844篇 |
2022年 | 8965篇 |
2021年 | 18942篇 |
2020年 | 14324篇 |
2019年 | 17960篇 |
2018年 | 13105篇 |
2017年 | 12571篇 |
2016年 | 14650篇 |
2015年 | 17873篇 |
2014年 | 31070篇 |
2013年 | 30364篇 |
2012年 | 31442篇 |
2011年 | 30344篇 |
2010年 | 26425篇 |
2009年 | 26341篇 |
2008年 | 24730篇 |
2007年 | 23968篇 |
2006年 | 20925篇 |
2005年 | 16095篇 |
2004年 | 11040篇 |
2003年 | 9705篇 |
2002年 | 7829篇 |
2001年 | 6638篇 |
2000年 | 5691篇 |
1999年 | 4533篇 |
1998年 | 4205篇 |
1997年 | 3960篇 |
1996年 | 3548篇 |
1995年 | 3652篇 |
1994年 | 3388篇 |
1993年 | 2834篇 |
1992年 | 2816篇 |
1991年 | 2538篇 |
1990年 | 2298篇 |
1989年 | 2122篇 |
1988年 | 1978篇 |
1987年 | 1699篇 |
1986年 | 1470篇 |
1985年 | 2677篇 |
1984年 | 2690篇 |
1983年 | 1894篇 |
1982年 | 2039篇 |
1981年 | 1848篇 |
1980年 | 1610篇 |
1979年 | 1344篇 |
1978年 | 1031篇 |
1977年 | 985篇 |
1976年 | 863篇 |
1975年 | 558篇 |
1974年 | 545篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
12.
13.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
14.
15.
16.
18.
《Journal of infection and chemotherapy》2022,28(2):352-355
IntroductionMonoclonal antibody therapy has been reported to be highly effective for preventing hospitalisation and severe cases in patients with Coronavirus Disease 2019 (COVID-19). However, since the drug is not readily available, it is important to rapidly and appropriately identify high-risk patients who can benefit most from therapy. Therefore, we designed a risk scoring system to identify at-risk COVID-19 patients in our region during the largest surge of COVID-19, from July to September 2021.MethodsAccording to the risk scores, confirmed COVID-19 patients were introduced to receive REGN-CoV-2 to our hospital by regional health centre from 18th August (Term 3). The primary outcome was the comparison of the number of hospitalisation and severe condition with other periods, the 4th wave (Term 1) and the early part of the 5th wave (Term 2) in Japan.ResultsDuring Term 3, 115 patients were stratified with the scoring system and administered REGN-COV-2. The number of hospitalisation vs severe cases were 60 (5.2%) vs 14 (1.2%), 8 (1.5%) vs 3 (0.6%) and 21 (1.2%) vs 2 (0.1%), in term 1, 2 and 3, respectively. Among those aged <60 years, compared with term 1, the relative risk of hospitalisation and severe condition were 0.25 (95% CI: 0.12–0.53) and 0.10 (95% CI: 0.01–0.80), respectively, in term 3. Drug adverse events were fever (3: 2.6%), headache (1: 0.9%) and neck rash (1: 0.9%), all events were resolved within 24 h wth no serious adverse event.ConclusionsThe administration of monoclonal antibody therapy using a risk scoring system significantly reduced the number of hospitalisation and disease severity of COVID-19 without any serious adverse events and avoided regional medical collapse. 相似文献
19.
目的:探索嘌呤能受体X1(purinergic receptor,P2RX1)与肺腺癌(LUAD)患者预后及免疫细胞浸润的相关性。方法:利用生物信息学技术分析非小细胞肺癌中P2RX1的表达及其甲基化与患者预后的关系,对P2RX1共表达基因进行富集分析并筛选核心基因。利用TIMER 2.0数据库、R软件等分析P2RX1与免疫细胞、免疫检查点、免疫基质评分等的相关性。结果:P2RX1在LUAD中表达下调,低表达P2RX1的患者预后较差(P<0.05),且P2RX1与肿瘤纯度、分期等临床病理因素有关(P<0.05)。P2RX1的表达与肺鳞癌患者预后无明显相关。Cg06475633等P2RX1 CpG位点甲基化与患者预后相关。P2RX1共表达基因主要富集于免疫细胞活化、分化等通路和生物学进程,核心基因主要包括BTK、IKZF1等。P2RX1的表达与B细胞浸润、免疫/基质评分、PD-1、CTLA-4等多个免疫检查点显著相关(P<0.05)。结论:P2RX1有望成为LUAD诊断和免疫治疗的新靶点。 相似文献
20.